# iThera Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ithera-medical

- Industry: Medical Devices & Equipment
- Headquarters: Munich, Germany
- Website: www.ithera-medical.com
- Total disclosed funding: $22M
- Latest round: Series D (Dec 22, 2022)
- Investors on record: 8

## About

Based in Germany, iThera Medical GmbH operates in the field of medical technology, specializing in advanced imaging systems that provide non-invasive insights into tissue biomarkers and disease progression.iThera Medical GmbH, founded in 2010 in Munich, Germany, focuses on innovative imaging solutions. The company has secured a total of 3 funding deals, with the most recent being a Series D round on December 22, 2022, raising EUR 13 million. The funding was backed by investors including TRUMPF Venture and the European Investment Fund. The company was founded by Vasilis Ntziachristos and is currently led by CEO Christian Wiest.iThera Medical specializes in next-generation imaging technology, particularly optoacoustic imaging systems that enable non-invasive visualization and quantification of disease-related tissue biomarkers. Their primary products, the MSOT Acuity and RSOM Explorer C50, cater to both clinical and preclinical research, helping assess muscle perfusion in conditions like Peripheral Arterial Disease (PAD) and investigating muscle degeneration in neuromuscular diseases, such as Pompe disease. Their technology serves academic research institutions, hospitals, and clinical research organizations predominantly in Europe and North America, addressing diagnostic challenges in cancer research, ischemia studies, and inflammatory diseases.iThera Medical generates revenue primarily through the sales of its imaging systems and related services to research institutions and medical facilities. Transactions are generally structured as direct B2B sales, where institutions purchase the MSOT Acuity and RSOM Explorer C50 for clinical and preclinical applications. These sales often include service agreements for maintenance and support, aimed at ensuring the equipment's longevity and performance. Their pricing reflects the high value of their imaging technology, tailored to meet the specific needs of their clientele.In December 2022, iThera Medical GmbH raised EUR 13 million in Series D funding, which will be used to support the development of their MSOT device and facilitate its expansion in Europe and the United States. The company plans to introduce new products in the coming years while strategically targeting growth in these key markets, enhancing their presence and operational capabilities.

## Funding rounds

- Series D, Dec 22, 2022, $14M — European Investment Fund, BayBG, Bayern Kapital, Mey Capital Matrix, Falk Strascheg Holding GmbH, TRUMPF Venture, Fluxunit, Occident Group
- Series C, Sep 13, 2018, $8.2M — BayBG, Bayern Kapital, Falk Strascheg Holding GmbH, Occident Group, Fluxunit
- Series A, Oct 27, 2011 — BayBG, Mey Capital Matrix

## Investors

- BayBG (https://capitalatlas.ai/funds/baybg) — Series A, Series C, Series D
- Mey Capital Matrix (https://capitalatlas.ai/funds/mey-capital-matrix) — Series A, Series D
- Bayern Kapital (https://capitalatlas.ai/funds/bayern-kapital) — Series C, Series D
- Falk Strascheg Holding GmbH — Series C, Series D
- Occident Group — Series C, Series D
- Fluxunit (https://capitalatlas.ai/funds/fluxunit) — Series C, Series D
- European Investment Fund (https://capitalatlas.ai/funds/european-investment-fund) — Series D
- TRUMPF Venture (https://capitalatlas.ai/funds/trumpf-venture) — Series D